IP Library Patent Application 18587858
Patent Application
App. No. 18/587,858

COMPOSITIONS AND KITS FOR DETECTING THE PRESENCE OF A HYPERVIRULENT CLOSTRIDIUM DIFFICILE STRAIN

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/587,858
Abstract

The present invention provides a nucleic acid amplification based method for detecting a hypervirulent Clostridium difficile strain in a biological sample. The present invention is based on the use of oligonucleotide primers and probes specific to negative and positive markers in hypervirulent Clostridium difficile genome.

Claims (24)

1 . An oligonucleotide primer set comprising a first oligonucleotide comprising or consisting of at least 10 contiguous nucleotides present in the nucleotide sequence as set forth in SEQ ID NO:5 and a second oligonucleotide comprising or consisting of at least 10 contiguous nucleotides present in the nucleotide sequence as set forth in SEQ ID NO:6, wherein the primer set amplifies a target sequence in the C. difficile genome, and wherein the primer set further comprises a probe for detecting the amplified target sequence, wherein the probe comprises one or more modified nucleotides and/or a fluorescent label, radiolabel, or phosphorescent label.

2 . The oligonucleotide primer set according to claim 1 , wherein the first oligonucleotide comprises the nucleotide sequence as set forth in SEQ ID NO:5 and the second oligonucleotide comprises the nucleotide sequence as set forth in SEQ ID NO:6.

3 . The oligonucleotide primer set according to claim 2 , wherein the first oligonucleotide consists of the nucleotide sequence as set forth in SEQ ID NO:5 and the second oligonucleotide consists of the nucleotide sequence as set forth in SEQ ID NO:6.

4 . The oligonucleotide primer set according to claim 1 , wherein the probe comprises at least 10 contiguous nucleotides present in the nucleotide sequence as set forth in SEQ ID NO:8 or SEQ ID NO:9.

5 . The oligonucleotide primer set according to claim 4 , wherein the probe comprises the nucleotide sequence as set forth in SEQ ID NO:8 or SEQ ID NO:9.

6 . The oligonucleotide primer set according to claim 1 , further comprising a second oligonucleotide primer set, wherein the second oligonucleotide primer set comprises a third oligonucleotide comprising or consisting of at least 10 contiguous nucleotides present in the nucleotide sequence as set forth in SEQ ID NO:3 and a fourth oligonucleotide comprising or consisting of at least 10 contiguous nucleotides present in the nucleotide sequence as set forth in SEQ ID NO:4, wherein the second oligonucleotide primer set amplifies a target sequence in the C. difficile hydR gene.

7 . The oligonucleotide primer set according to claim 6 , wherein the third oligonucleotide comprises or consists of the nucleotide sequence as set forth in SEQ ID NO:3 and the fourth oligonucleotide comprises or consists of the nucleotide sequence as set forth in SEQ ID NO:4.

8 . The oligonucleotide primer set according to claim 6 , further comprising a probe for detecting the amplified hydR target sequence, said probe comprising at least 10 contiguous nucleotides present in the nucleotide sequence as set forth in SEQ ID NO:7.

9 . The oligonucleotide primer set according to claim 8 , wherein the probe for detecting the amplified hydR target sequence comprises the nucleotide sequence as set forth in SEQ ID NO:7.

10 . The oligonucleotide primer set according to claim 6 , further comprising a third oligonucleotide primer set, wherein the third oligonucleotide primer set comprises a fifth oligonucleotide comprising or consisting of at least 10 contiguous nucleotides present in the nucleotide sequence as set forth in SEQ ID NO:11 and a sixth oligonucleotide comprising or consisting of at least 10 contiguous nucleotides present in the nucleotide sequence as set forth in SEQ ID NO:12, wherein the third oligonucleotide primer set amplifies a target sequence in the C. difficile tcdB gene.

11 . The oligonucleotide primer set according to claim 10 , wherein the fifth oligonucleotide comprises or consists of the nucleotide sequence as set forth in SEQ ID NO:11 and the sixth oligonucleotide comprises or consists of the nucleotide sequence as set forth in SEQ ID NO:12.

12 . The oligonucleotide primer set according to claim 10 , further comprising a probe for detecting the amplified tcdB target sequence, said probe comprising at least 10 contiguous nucleotides present in the nucleotide sequence as set forth in SEQ ID NO:13.

13 . The oligonucleotide primer set according to claim 12 , wherein the probe for detecting the amplified tedB target sequence comprises the nucleotide sequence as set forth in SEQ ID NO:13.

14 . A kit for detecting a hypervirulent C. difficile strain in a biological sample, the kit comprising:

(i) an oligonucleotide primer set comprising a first oligonucleotide comprising or consisting of at least 10 contiguous nucleotides present in the nucleotide sequence as set forth in SEQ ID NO:5 and a second oligonucleotide comprising or consisting of at least 10 contiguous nucleotides present in the nucleotide sequence as set forth in SEQ ID NO:6, wherein the primer set amplifies a target sequence in the C. difficile genome;

(ii) a probe for detecting the amplified target sequence, wherein the probe comprises one or more modified nucleotides and/or a fluorescent label, radiolabel, or phosphorescent label; and

(iii) a reagent for performing amplification of a nucleic acid.

15 . The kit of claim 14 , wherein the reagent is selected from the group consisting of a DNA polymerase, dNTPs, and a buffer.

16 . The kit of claim 14 , wherein the first oligonucleotide comprises or consists of the nucleotide sequence as set forth in SEQ ID NO:5 and the second oligonucleotide comprises or consists of the nucleotide sequence as set forth in SEQ ID NO:6.

17 . The kit of claim 14 , wherein the probe comprises at least 10 contiguous nucleotides present in the nucleotide sequence as set forth in SEQ ID NO:8 or SEQ ID NO:9.

18 . The kit of claim 14 , further comprising a second oligonucleotide primer set, wherein the second oligonucleotide primer set comprises a third oligonucleotide comprising or consisting of at least 10 contiguous nucleotides present in the nucleotide sequence as set forth in SEQ ID NO:3 and a fourth oligonucleotide comprising or consisting of at least 10 contiguous nucleotides present in the nucleotide sequence as set forth in SEQ ID NO:4, wherein the second oligonucleotide primer set amplifies a target sequence in the C. difficile hydR gene.

19 . The kit of claim 18 , wherein the third oligonucleotide comprises or consists of the nucleotide sequence as set forth in SEQ ID NO:3 and the fourth oligonucleotide comprises or consists of the nucleotide sequence as set forth in SEQ ID NO:4.

20 . The kit of claim 18 , further comprising a third oligonucleotide primer set, wherein the third oligonucleotide primer set comprises a fifth oligonucleotide comprising or consisting of at least 10 contiguous nucleotides present in the nucleotide sequence as set forth in SEQ ID NO:11 and a sixth oligonucleotide comprising or consisting of at least 10 contiguous nucleotides present in the nucleotide sequence as set forth in SEQ ID NO:12, wherein the third oligonucleotide primer set amplifies a target sequence in the C. difficile tcdB gene.

21 . The kit of claim 20 , wherein the fifth oligonucleotide comprises or consists of the nucleotide sequence as set forth in SEQ ID NO:11 and the sixth oligonucleotide comprises or consists of the nucleotide sequence as set forth in SEQ ID NO: 12.

Assignments (4)
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075926/0339 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2025
From: MOBIDIAG OY
To: GEN-PROBE INCORPORATED
Reel/Frame 071007/0221 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2024
From: KIRVESKARI, JUHA; KURKELA, JAAKKO
To: MOBIDIAG LTD
Reel/Frame 066830/0842 →